XBiotech has concluded a Phase II pilot study to test MABp1 in patients with Type 2 diabetes. The study was headed by world-leading diabetes expert Dr. Marc Donath, Head of Endocrinology, Diabetes and Metabolism at University Hospital of Basel, Switzerland. Remarkable findings in this study have provided the basis to advance clinical programs in Type 2 diabetes.
Type 2 Diabetes is one of the fastest-growing and most significant disease burdens among industrialized societies. New treatment options are needed to prevent progression of disease and loss of pancreatic function in Type 2 diabetic patients.
Inflammatory cells infiltrate white adipose tissue and the pancreas, resulting in the development of insulin resistance and loss of insulin production, respectively. When inflammation makes adipose cells insensitive to insulin, they can no longer take up sugar, making control of blood sugar levels difficult.
The pancreas can initially compensate for reduced insulin sensitivity by increasing output of insulin. However, this increased load results in stress on the pancreas and an inflammatory process can ensue in the pancreas itself. Current drugs, such as linagliptin, worsen this process by stimulating the pancreas to produce insulin and furthering stress on the pancreas.
The mechanism of action of XBiotech's antibody therapy — to reduce inflammation that compromises pancreas function and glycemic control — could enhance glycemic control by improving the overall status of the systemic inflammatory condition present in Type 2 diabetics. This represents a breakthrough in management of the disease.